NAMPT Inhibitor Market by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2035
![](/report_cover/10031/nampt-inhibitor-market-by-type-of-molecule-small-molecules-n-biologics-therapeutic-area-oncological-n-respiratory-disorders-indication-non-hodgkin_en.gif)
The NAMPT inhibitor market is projected to experience a substantial growth with a compound annual growth rate (CAGR) of 15% during the forecast period, driven by the escalating burden of cancer patients. A study published in the American Cancer Society Journal has estimated that by 2040, the number of cancer cases will surpass 28 million, reflecting a cumulative growth of nearly 47% since 2020. This persistent rise in cancer patient numbers places a significant strain on both financial and healthcare resources. Notably, the annual expenditure related to cancer care in the US alone exceeds USD 200 billion.
As the majority of current cancer treatment options, particularly for late-stage cancers, are deemed inadequate, there is a pressing demand for highly effective therapeutics. Over time, numerous research studies have revealed that NAMPT (Nicotinamide Phosphoribosyl Transferase) can disrupt the metabolism of NAD+, which serves as the fuel for tumor cells. This concept has spurred extensive research into the development of novel and efficacious drug candidates, namely NAMPT inhibitors. NAMPT inhibitors are under evaluation for a wide range of indications, with a primary focus on oncological disorders. Encouraging research outcomes have garnered significant attention from private and public investors, resulting in investments exceeding USD 650 million since 2018. Fueled by increasing R&D activities, promising clinical data, and substantial financial support, the NAMPT inhibitor market is poised for remarkable growth in the forecast period.
Key Market Segments
Type of Molecule
As the majority of current cancer treatment options, particularly for late-stage cancers, are deemed inadequate, there is a pressing demand for highly effective therapeutics. Over time, numerous research studies have revealed that NAMPT (Nicotinamide Phosphoribosyl Transferase) can disrupt the metabolism of NAD+, which serves as the fuel for tumor cells. This concept has spurred extensive research into the development of novel and efficacious drug candidates, namely NAMPT inhibitors. NAMPT inhibitors are under evaluation for a wide range of indications, with a primary focus on oncological disorders. Encouraging research outcomes have garnered significant attention from private and public investors, resulting in investments exceeding USD 650 million since 2018. Fueled by increasing R&D activities, promising clinical data, and substantial financial support, the NAMPT inhibitor market is poised for remarkable growth in the forecast period.
Key Market Segments
Type of Molecule
- Small Molecules
- Biologics
- Oncological Disorders
- Respiratory Disorders
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Acute Respiratory Distress Syndrome
- Acute Myeloid Leukemia
- Oral
- Intravenous
- First Line
- Second Line
- North America
- Europe
- Asia-Pacific
- Rest of the World
- The report studies the NAMPT inhibitor market by type of molecule, therapeutic area, indication, route of administration, line of treatment and key geographical regions
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
- The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
- The report forecasts the revenue of market segments with respect to major regions.
- A comprehensive overview of the current market landscape for NAMPT targeting drug candidates currently under research in pre-clinical and clinical studies.
- A detailed analysis of recent partnerships and collaborations among stakeholders in the NAMPT inhibitor domain since 2022.
- An insightful analysis of recent funding instances reported by players in the NAMPT inhibitor market, including information on the year of funding, the amount received, and the type of funding.
- An in-depth analysis of various grants received by players in this field since 2022, based on the year of the award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.
- An insightful company competitiveness analysis of NAMPT inhibitor therapy developers based on various relevant parameters, such as portfolio strength, partnership strength and funding strength.
- Comprehensive profiles of prominent players engaged in the development of NAMPT inhibitors, providing an overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments, and an informed future outlook.
- A detailed analysis of several peer-reviewed scientific articles related to research on NAMPT inhibitors over the last 12 years, based on parameters such as the year of publication, type of publication, and popular keywords.
- An analysis of global events attended by industry players, considering various parameters such as the year of the event, event platform, type of event, leading presenters (in terms of the number of participations), and leading players (in terms of the number of participations).
- An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter. This analysis considers parameters like the year of the tweet, top users, and emerging focus areas.
- An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, considering various relevant parameters, such as the phase of discontinuation, target indication, route of administration, and type of molecule.
- A proprietary analysis of various competitive strategies that can be implemented by drug developers in the NAMPT inhibitor market to expedite the FDA approval process for their proprietary products. This analysis includes information on various parameters, such as clinical evidence, awards/grants, research findings, partnerships, other financial support received, and more.
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the container closure integrity testing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
- You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.
- Antengene Therapeutics
- Aqualung Therapeutics
- Karyopharm Therapeutics
- OncoTartis
- Onxeo
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. Overview of NAMPT Inhibitors
2.2. Key Historical Events Related to NAMPT Inhibitors
2.3. NAMPT Inhibitors: Recent Activity
2.4. NAMPT Inhibitors: Mechanism of Action
2.5. NAMPT Inhibitors: Key Target Indications
3. MARKET LANDSCAPE
3.1. NAMPT Inhibitors: Pipeline Review
3.1.1. Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Type of Therapy
3.1.5. Analysis by Line of Treatment
3.1.5. Analysis by Route of Administration
3.2. NAMPT Inhibitors: Developer Landscape
3.2.1. Analysis by Type of Player
3.2.2. Analysis by Year of Establishment
3.2.3. Analysis by Location of Headquarters
3.2.4. Analysis by Location of Headquarters and Stage of Development
3.2.5. Analysis by Location of Headquarters and Phase of Development
3.2.6. Analysis by Location of Headquarters and Type of Molecule
4. PARTNERSHIPS AND COLLABORATIONS
4.1. NAMPT Inhibitors: Partnerships and Collaborations
4.1.1. Analysis by Year of Partnership
4.1.2. Analysis by Type of Partnership
4.1.3. Analysis by Year and Type of Partnership
4.1.4. Analysis by Type of Agreement
4.1.5. Analysis by Intercontinental and Intracontinental Deals
4.1.6. Active Players: Analysis by Number of Partnerships
5. FUNDING AND INVESTMENTS
5.1. NAMPT Inhibitors: Funding and Investments
5.1.1. Analysis of Instances by Year
5.1.2. Analysis of Amount Raised by Year
5.1.3. Analysis of Number of Instances Year and Type of Funding
5.1.4. Analysis of Amount Raised by Year and Type of Funding
5.1.5. Analysis of Number of Instances by Type of Funding
5.1.6. Analysis of Amount Raised by Type of Funding
5.1.7. Most Active Investors: Analysis by Number of Funding Instances
5.1.8. Active Players: Analysis by Number of Instances
5.1.9. Active Players: Analysis by Amount Raised
5.1.10. Analysis of Instances by Geography
5.1.11. Analysis of Total Amount Raised by Geography
5.1.12. Analysis of Total Amount Raised by Year of Establishment
5.1.13. Concluding Remarks
6. GRANTS ANALYSIS
6.1. Scope and Methodology
6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
6.2.1. Analysis of Instances by Year
6.2.2. Analysis of Amount Awarded by Year
6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
6.2.4. Prominent Program Officers: Analysis by Number of Grants
6.2.5. Analysis by Type of Recipient Organization
6.2.6. Analysis of Instances by Year
6.2.7. Analysis by Purpose of Grant Award
6.2.8. Analysis by Funding Institute
6.2.9. Analysis by Support Period
6.2.10. Analysis by Funding Institute and Support Period
6.2.11. Analysis by Activity Code
6.2.12. Analysis by Type of Application
6.2.13. Word Cloud of NIH Spending Categories
7. COMPANY COMPETITIVENESS
7.1. Key Assumptions and Parameters
7.2. Methodology
7.3. Benchmarking of Portfolio Strength
7.4. Benchmarking of Partnership Activity
7.5. Benchmarking of Funding Activity
7.6. Benchmarking of Portfolio Strength
7.7. NAMPT Inhibitors: Company Competitiveness Analysis
8. COMPANY PROFILES
8.1. Antengene Therapeutics
8.1.1. Company Overview
8.1.2. Funding Information
8.1.3. Product Portfolio
8.1.4. Recent Developments and Future Outlook
8.2. Aqualung Therapeutics
8.2.1. Company Overview
8.2.2. Funding Information
8.2.3. Product Portfolio
8.2.4. Patent Portfolio
8.2.5. Recent Developments and Future Outlook
8.3. Karyopharm Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.4. Patent Portfolio
8.3.5. Recent Developments and Future Outlook
8.4. OncoTartis
8.4.1. Company Overview
8.4.2. Funding Information
8.4.3. Product Portfolio
8.4.4. Patent Portfolio
8.4.5. Recent Developments and Future Outlook
8.5. Onxeo
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook
9. PUBLICATION ANALYSIS
9.1. Methodology and Key Parameters
9.2. NAMPT Inhibitors: List of Publications
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Most Popular Journals: Analysis by Number of Publications
9.2.4. Most Popular Publishers: Analysis by Number of Publications
9.2.5. Analysis by Journal Impact Factor
9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
9.2.7. Analysis by Geography
9.2.8. Emerging Focus Areas
10. GLOBAL EVENTS ANALYSIS
10.1. Methodology and Key Parameters
10.2. NAMPT Inhibitors: List of Global Events
10.2.2. Cumulative Year-wise Trend
10.2.3. Analysis by Type of Event
10.2.4. Analysis by Event Platform
10.2.5. Leading Players: Analysis by Number of Participants
10.2.6. Leading Presenters: Analysis by Number of Participants
10.2.7. Analysis by Geography
11. SOCIAL MEDIA ANALYSIS
11.1. Methodology and Key Parameters
11.1.1. Cumulative Year-wise Activity
11.1.2. Leading Users: Analysis by Number of Tweets
11.1.3. Trending Words / Phrases on Twitter
12. DRUG FAILURE ANALYSIS
12.1. Methodology and Key Parameters
12.2. NAMPT Inhibitors: List of Failed Drug Candidates
12.2.1. Analysis by Phase of Discontinuation
12.2.2. Analysis by Trial Status
12.2.3. Analysis by Target Indication
12.2.4. Analysis by Route of Administration
12.2.5. Analysis by Type of Sponsor
12.2.6. Affiliated Stakeholders: Analysis by Number of Trials
12.2.7. Analysis by Reasons for Drug Failure
12.2.8. Key Terms in Study Results
12.2.9. Other Plausible Reasons for Drug Failure
13. FDA APPROVAL STRATEGIES
13.1. Methodology and Key Parameters
13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
13.3. Drug Specific Business Models followed by Company
13.4. Analysis of Drug Candidates by Business Model
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Key Assumptions and Parameters
14.2. Forecast Methodology
14.3. Global NAMPT Inhibitors Market, 2027-2040
14.4. List of Forecasted Drugs
14.4.1. OT-82, OncoTartis
14.4.1.1. Global Sales Forecast
14.4.1.2. Regional Sales Forecast
14.4.1.3. Net Present Value
14.4.1.4. Value Creation Analysis
14.4.2. ALT-100, Aqualung Therapeutics
14.4.2.1. Global Sales Forecast
14.4.2.2. Regional Sales Forecast
14.4.2.3. Net Present Value
14.4.2.4. Value Creation Analysis
14.4.3. ATG-019, Antengene Therapeutics
14.4.3.1. Global Sales Forecast
14.4.3.2. Regional Sales Forecast
14.4.3.3. Net Present Value
14.4.3.4. Value Creation Analysis
14.4.4. KPT-9274, Karyopharm Therapeutics
14.4.4.1. Global Sales Forecast
14.4.4.2. Regional Sales Forecast
14.4.4.3. Net Present Value
14.4.4.4. Value Creation Analysis
14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040
14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040
14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040
14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040
14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040
14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040
14.10. NAMPT Inhibitors: Market Share of Key Players
14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: LIST OF FIGURES
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
2. INTRODUCTION
2.1. Overview of NAMPT Inhibitors
2.2. Key Historical Events Related to NAMPT Inhibitors
2.3. NAMPT Inhibitors: Recent Activity
2.4. NAMPT Inhibitors: Mechanism of Action
2.5. NAMPT Inhibitors: Key Target Indications
3. MARKET LANDSCAPE
3.1. NAMPT Inhibitors: Pipeline Review
3.1.1. Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Type of Therapy
3.1.5. Analysis by Line of Treatment
3.1.5. Analysis by Route of Administration
3.2. NAMPT Inhibitors: Developer Landscape
3.2.1. Analysis by Type of Player
3.2.2. Analysis by Year of Establishment
3.2.3. Analysis by Location of Headquarters
3.2.4. Analysis by Location of Headquarters and Stage of Development
3.2.5. Analysis by Location of Headquarters and Phase of Development
3.2.6. Analysis by Location of Headquarters and Type of Molecule
4. PARTNERSHIPS AND COLLABORATIONS
4.1. NAMPT Inhibitors: Partnerships and Collaborations
4.1.1. Analysis by Year of Partnership
4.1.2. Analysis by Type of Partnership
4.1.3. Analysis by Year and Type of Partnership
4.1.4. Analysis by Type of Agreement
4.1.5. Analysis by Intercontinental and Intracontinental Deals
4.1.6. Active Players: Analysis by Number of Partnerships
5. FUNDING AND INVESTMENTS
5.1. NAMPT Inhibitors: Funding and Investments
5.1.1. Analysis of Instances by Year
5.1.2. Analysis of Amount Raised by Year
5.1.3. Analysis of Number of Instances Year and Type of Funding
5.1.4. Analysis of Amount Raised by Year and Type of Funding
5.1.5. Analysis of Number of Instances by Type of Funding
5.1.6. Analysis of Amount Raised by Type of Funding
5.1.7. Most Active Investors: Analysis by Number of Funding Instances
5.1.8. Active Players: Analysis by Number of Instances
5.1.9. Active Players: Analysis by Amount Raised
5.1.10. Analysis of Instances by Geography
5.1.11. Analysis of Total Amount Raised by Geography
5.1.12. Analysis of Total Amount Raised by Year of Establishment
5.1.13. Concluding Remarks
6. GRANTS ANALYSIS
6.1. Scope and Methodology
6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
6.2.1. Analysis of Instances by Year
6.2.2. Analysis of Amount Awarded by Year
6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
6.2.4. Prominent Program Officers: Analysis by Number of Grants
6.2.5. Analysis by Type of Recipient Organization
6.2.6. Analysis of Instances by Year
6.2.7. Analysis by Purpose of Grant Award
6.2.8. Analysis by Funding Institute
6.2.9. Analysis by Support Period
6.2.10. Analysis by Funding Institute and Support Period
6.2.11. Analysis by Activity Code
6.2.12. Analysis by Type of Application
6.2.13. Word Cloud of NIH Spending Categories
7. COMPANY COMPETITIVENESS
7.1. Key Assumptions and Parameters
7.2. Methodology
7.3. Benchmarking of Portfolio Strength
7.4. Benchmarking of Partnership Activity
7.5. Benchmarking of Funding Activity
7.6. Benchmarking of Portfolio Strength
7.7. NAMPT Inhibitors: Company Competitiveness Analysis
8. COMPANY PROFILES
8.1. Antengene Therapeutics
8.1.1. Company Overview
8.1.2. Funding Information
8.1.3. Product Portfolio
8.1.4. Recent Developments and Future Outlook
8.2. Aqualung Therapeutics
8.2.1. Company Overview
8.2.2. Funding Information
8.2.3. Product Portfolio
8.2.4. Patent Portfolio
8.2.5. Recent Developments and Future Outlook
8.3. Karyopharm Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.4. Patent Portfolio
8.3.5. Recent Developments and Future Outlook
8.4. OncoTartis
8.4.1. Company Overview
8.4.2. Funding Information
8.4.3. Product Portfolio
8.4.4. Patent Portfolio
8.4.5. Recent Developments and Future Outlook
8.5. Onxeo
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook
9. PUBLICATION ANALYSIS
9.1. Methodology and Key Parameters
9.2. NAMPT Inhibitors: List of Publications
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Most Popular Journals: Analysis by Number of Publications
9.2.4. Most Popular Publishers: Analysis by Number of Publications
9.2.5. Analysis by Journal Impact Factor
9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
9.2.7. Analysis by Geography
9.2.8. Emerging Focus Areas
10. GLOBAL EVENTS ANALYSIS
10.1. Methodology and Key Parameters
10.2. NAMPT Inhibitors: List of Global Events
10.2.2. Cumulative Year-wise Trend
10.2.3. Analysis by Type of Event
10.2.4. Analysis by Event Platform
10.2.5. Leading Players: Analysis by Number of Participants
10.2.6. Leading Presenters: Analysis by Number of Participants
10.2.7. Analysis by Geography
11. SOCIAL MEDIA ANALYSIS
11.1. Methodology and Key Parameters
11.1.1. Cumulative Year-wise Activity
11.1.2. Leading Users: Analysis by Number of Tweets
11.1.3. Trending Words / Phrases on Twitter
12. DRUG FAILURE ANALYSIS
12.1. Methodology and Key Parameters
12.2. NAMPT Inhibitors: List of Failed Drug Candidates
12.2.1. Analysis by Phase of Discontinuation
12.2.2. Analysis by Trial Status
12.2.3. Analysis by Target Indication
12.2.4. Analysis by Route of Administration
12.2.5. Analysis by Type of Sponsor
12.2.6. Affiliated Stakeholders: Analysis by Number of Trials
12.2.7. Analysis by Reasons for Drug Failure
12.2.8. Key Terms in Study Results
12.2.9. Other Plausible Reasons for Drug Failure
13. FDA APPROVAL STRATEGIES
13.1. Methodology and Key Parameters
13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
13.3. Drug Specific Business Models followed by Company
13.4. Analysis of Drug Candidates by Business Model
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Key Assumptions and Parameters
14.2. Forecast Methodology
14.3. Global NAMPT Inhibitors Market, 2027-2040
14.4. List of Forecasted Drugs
14.4.1. OT-82, OncoTartis
14.4.1.1. Global Sales Forecast
14.4.1.2. Regional Sales Forecast
14.4.1.3. Net Present Value
14.4.1.4. Value Creation Analysis
14.4.2. ALT-100, Aqualung Therapeutics
14.4.2.1. Global Sales Forecast
14.4.2.2. Regional Sales Forecast
14.4.2.3. Net Present Value
14.4.2.4. Value Creation Analysis
14.4.3. ATG-019, Antengene Therapeutics
14.4.3.1. Global Sales Forecast
14.4.3.2. Regional Sales Forecast
14.4.3.3. Net Present Value
14.4.3.4. Value Creation Analysis
14.4.4. KPT-9274, Karyopharm Therapeutics
14.4.4.1. Global Sales Forecast
14.4.4.2. Regional Sales Forecast
14.4.4.3. Net Present Value
14.4.4.4. Value Creation Analysis
14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040
14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040
14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040
14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040
14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040
14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040
14.10. NAMPT Inhibitors: Market Share of Key Players
14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: LIST OF FIGURES
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS